Jaguar Health, Inc., incorporated in Delaware and headquartered in San Francisco, is an emerging pharmaceuticals company focused on developing and commercializing novel, plant-based, sustainably derived gastrointestinal products on a global basis. It aims to develop targeted products that draw on its intellectual property portfolio, product pipeline and extensive botanical library to address unmet medical needs.<\/p>\n
Through its wholly owned subsidiary Napo Pharmaceuticals, Inc., Jaguar develops gastrointestinal pharmaceuticals from plants harvested sustainably in rainforest areas. Napo’s FDA-approved drug Mytesi (crofelemer) is indicated for the symptomatic relief of noninfectious diarrhea in adults with HIV\/AIDS on antiretroviral therapy. The Company was pursuing follow-on indications for crofelemer, including cancer therapy-related diarrhea, and seeking partnerships to move pipeline indications into pivotal clinical trials. For 2020 it reported Mytesi net sales of about $9.3 million, up 64% from the year before.<\/p>\n
NASDAQ: JAGX \u00b7 Pharmaceuticals<\/p>\n
Read the updated corporate profile (PDF, 3 pages)<\/a><\/p>\n